SEC16B

SEC16B is a scaffold protein at ER exit sites that organizes COPII vesicle assembly for the export of diverse cargoes, including peroxisomal biogenesis factors (Pex16, Pex3), type I procollagen, and large APOB-containing lipoproteins (chylomicrons and VLDL), with its C-terminal domain conferring functions distinct from the paralog SEC16A (PMID:21768384, PMID:22279616, PMID:36916446, PMID:36796587). In the liver, SEC16B fine-tunes COPII condensation to calibrate lipoprotein export, is transcriptionally regulated by HNF4A, and additionally localizes to ER–lipid droplet contact sites where it promotes lipid droplet expansion; hepatic deletion markedly lowers circulating APOB, triglycerides, and cholesterol and protects against atherosclerosis (PMID:42030462, PMID:42032080). SEC16B is transcriptionally induced by ER stress through XBP1- and ATF4-responsive elements in its promoter and first intron (PMID:32815086), and in pancreatic beta cells it supports cholinergic signaling and Ca²⁺-dependent glucose-stimulated insulin secretion (PMID:40705078). A homozygous loss-of-function SEC16B mutation causes osteogenesis imperfecta through impaired procollagen ER export (PMID:36916446).

1. 2011 High

   Establishing that SEC16B is a non-redundant COPII scaffold at ER exit sites resolved the question of whether the two mammalian Sec16 paralogs serve overlapping or distinct functions, and revealed a specific role for SEC16B in ER-to-peroxisome trafficking of Pex16 and Pex3.

   Evidence RNAi knockdown, overexpression, rescue with RNAi-resistant construct, FRAP, and domain-deletion analysis in mammalian cells

   PMID:21768384 PMID:22279616 PMID:22355596

   Open questions at the time

   • Mechanism by which the SEC16B C-terminal domain specifically recognizes peroxisomal cargo is unknown
   • Whether SEC16B interacts directly with Pex16/Pex3 or acts indirectly through COPII components was not determined
2. 2020 Medium

   Identifying ER stress-responsive regulatory elements (UPRE and ATF4-binding site) in the SEC16B locus established that SEC16B expression is transcriptionally upregulated during the unfolded protein response, linking ER proteostasis to COPII capacity.

   Evidence Microarray, RT-PCR, and luciferase reporter assays with XBP1 and ATF4 in Neuro2a cells

   PMID:32815086

   Open questions at the time

   • Functional consequence of ER stress-induced SEC16B upregulation on COPII trafficking throughput was not measured
   • Whether the UPRE and ATF4 elements are conserved across species or cell types was not examined
3. 2023 High

   Discovery that a homozygous SEC16B missense mutation causes osteogenesis imperfecta, with procollagen accumulation in the ER rescued by wild-type SEC16B, proved that SEC16B is essential for large-cargo ER export in humans and linked it to a Mendelian disease.

   Evidence Patient fibroblast analysis with immunofluorescence, ER trafficking assays, and wild-type rescue transfection

   PMID:36916446

   Open questions at the time

   • How SEC16B enables packaging of oversized procollagen into COPII carriers is mechanistically unresolved
   • Whether other collagen types or large ECM cargoes are similarly affected was not tested
4. 2023 High

   Intestinal-specific Sec16b knockout demonstrated that SEC16B is required for apoB lipidation and chylomicron secretion, establishing it as a rate-limiting factor in dietary lipid absorption and a contributor to diet-induced obesity.

   Evidence Conditional intestinal knockout mice with acute lipid challenge, fasting/HFD refeeding, and serum triglyceride measurements

   PMID:36796587

   Open questions at the time

   • Whether SEC16B directly participates in pre-chylomicron transport vesicle formation or acts upstream on apoB lipidation was not resolved
   • Sex-specific protection from obesity (female mice) was not mechanistically explained
5. 2025 High

   Sec16b deletion in pancreatic beta cells revealed an unexpected role in glucose-stimulated insulin secretion via cholinergic signaling and Ca²⁺ influx, extending SEC16B function beyond ER export scaffolding to endocrine cell physiology.

   Evidence Conditional knockout mice, GSIS assays, intracellular Ca²⁺ measurements, islet RNA-seq, and Drosophila RNAi epistasis

   PMID:40705078

   Open questions at the time

   • The molecular link between SEC16B and cholinergic receptor surface expression or signaling is undefined
   • Whether the insulin secretion defect reflects impaired COPII-mediated trafficking of specific ion channels or receptors was not determined
6. 2026 High

   Hepatic Sec16b studies revealed a dual mechanism: SEC16B acts as a molecular brake fine-tuning COPII condensation for APOB-lipoprotein export and also localizes to ER–lipid droplet contact sites to promote LD expansion, with hepatic deletion reducing serum lipids and atherosclerosis.

   Evidence Hepatic conditional knockout mice, VLDL secretion assays, ER–LD contact site imaging, atherosclerosis models (Ldlr-null), HNF4A transcriptional regulation, and AI-driven COPII condensation modeling

   PMID:42030462 PMID:42032080

   Open questions at the time

   • Structural basis for SEC16B's brake function on COPII condensation lacks experimental validation
   • How SEC16B is targeted to ER–LD contact sites and whether it interacts with known LD-tethering machinery is unknown
   • Long-term metabolic consequences of hepatic SEC16B loss remain to be assessed

• The structural basis of SEC16B's distinct C-terminal domain, its mechanism for modulating COPII condensate dynamics, and the molecular pathway linking it to cholinergic signaling in beta cells remain open questions.
• No high-resolution structure of SEC16B or its COPII interaction interfaces exists
• Whether SEC16B directly contacts APOB or acts solely through COPII remodeling is unresolved
• Cell-type-specific roles beyond intestine, liver, and beta cells are largely unexplored